Content Currently Unavailable
Article | 2026 Clinical Trials at the Summit
Four-Year OPTIC Data Highlight Durability of Ixo-vec
Carl Danzig, MD, reviews long-term outcomes from the OPTIC trial, including an 86% annualized reduction in anti-VEGF injections through year 4.
Content Currently Unavailable







